Alembic (India) Investor Sentiment

ALEMBICLTD   100.08  2.91  2.99%   
About 55% of Alembic's shareholders are presently thinking to get in. The analysis of overall sentiment of trading Alembic Limited stock suggests that some investors are interested at this time. The current market sentiment, together with Alembic's historical and current headlines, can help investors time the market. In addition, many technical investors use Alembic Limited stock news signals to limit their universe of possible portfolio assets.
  
over a week ago at news.google.com         
Alembic Pharma down 3 percent on getting USFDA observation for its Vadodara plant - Business Standar...
Google News at Macroaxis
over a month ago at news.google.com         
Alembic Pharmas Vadodara Plant Gets VAI Status from US FDA - Indiainfoline
Google News at Macroaxis
over a month ago at news.google.com         
Alembic Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 20...
Google News at Macroaxis
over a month ago at news.google.com         
Alembic Pharma Q3 Review - Dolat Capital Maintains Reduce On The Stock, Revises Target Price Heres W...
Google News at Macroaxis
over a month ago at news.google.com         
Alembic Pharma Q3 Results Consolidated net profit declines 23 percent to 138 crore, stock down 5 per...
Google News at Macroaxis
over two months ago at news.google.com         
Alembic Limited Announces Demise of Mayank Amin as Non-Executive Independent Director - Marketscreen...
Google News at Macroaxis
over three months ago at news.google.com         
Heres why Alembic Pharma was buzzing in trade on December 20, details here - Business Standard
Google News at Macroaxis
over three months ago at news.google.com         
Stocks in news Ultratech, Paytm, LT, Biocon, Alembic Pharma - The Economic Times
Google News at Macroaxis
over three months ago at news.google.com         
Alembic Pharmaceuticals Dissolves Six Step-Down Subsidiaries - NDTV Profit
Google News at Macroaxis
over three months ago at news.google.com         
Alembic Ltd. - Economic Times
Google News at Macroaxis
over three months ago at news.google.com         
Alembic Pharma gets tentative USFDA nod for Olopatadine drug stock up 2 percent - Business Standard
Google News at Macroaxis
over three months ago at news.google.com         
Alembic Pharma gets USFDA nod for hypertension treatment drug - CNBCTV18
Google News at Macroaxis
over three months ago at news.google.com         
Q2FY25 Alembic Pharmas profit rises 12 percent to Rs 153 Crores Reports dip US sales growth - The Fi...
Google News at Macroaxis
over three months ago at news.google.com         
Alembic Pharmaceuticals Ltd. Remains a Strong Player in the Pharmaceutical Industry - MarketsMojo
Google News at Macroaxis
over three months ago at news.google.com         
Alembic Pharma shares hit 52-week high after Gujarat plant clears USFDA inspection - CNBCTV18
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Alembic that are available to investors today. That information is available publicly through Alembic media outlets and privately through word of mouth or via Alembic internal channels. However, regardless of the origin, that massive amount of Alembic data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Alembic news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Alembic relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Alembic's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Alembic alpha.

Alembic Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Alembic Pharma Q3 Review - Dolat Capital Maintains Reduce On The Stock, Revises Target Price Heres Why - NDTV Profit
02/04/2025

Complementary Tools for Alembic Stock analysis

When running Alembic's price analysis, check to measure Alembic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alembic is operating at the current time. Most of Alembic's value examination focuses on studying past and present price action to predict the probability of Alembic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alembic's price. Additionally, you may evaluate how the addition of Alembic to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets